BUSINESS
PIII Study of Opdivo in Renal Cell Carcinoma Ends Early Based on Favorable Results: Ono, BMS
The multinational PIII CheckMate-025 study of the anti-PD-1 antibody Opdivo (nivolumab) in patients with renal cell carcinoma (RCC) has ended early based on its superior overall survival (OS) against a comparator drug, Ono Pharmaceutical and Bristol-Myers Squibb (BMS) have jointly…
To read the full story
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





